A comprehensive review of clinical and laboratory evidence has identified a critical "Goldilocks zone" for testosterone levels in men, suggesting that both abnormally low and excessively high levels of the hormone significantly increase the risk of developing atrial fibrillation (AFib). The study, published in the Journal of the Endocrine Society, calls for a paradigm shift in how testosterone replacement therapy (TRT) is administered, moving away from a one-size-fits-all approach toward a more personalized, meticulously monitored model of care.
According to the research team, led by Rajat S. Barua, MD, PhD, of the Kansas City Veterans Affairs Medical Center, the relationship between testosterone and heart rhythm follows a distinct U-shaped pattern. This finding is particularly relevant as TRT prescriptions have surged over the last two decades among middle-aged and older men seeking to address symptoms of hypogonadism, such as fatigue, decreased libido, and muscle loss. However, the cardiovascular safety of these treatments remains a subject of intense medical scrutiny.
The Intersection of Endocrinology and Cardiac Health
Atrial fibrillation is a common heart rhythm disorder characterized by an irregular and often rapid heart rate. This condition can lead to blood clots, stroke, heart failure, and other heart-related complications. For many patients, a diagnosis of AFib necessitates lifelong management, including the use of anticoagulants (blood thinners) to mitigate stroke risk.
The review highlights that the heart is an androgen-sensitive organ. Testosterone receptors are present throughout cardiac tissue, and the hormone plays a vital role in regulating the electrical signals that coordinate the heart’s pumping action. Dr. Barua notes that because TRT is so widely prescribed, understanding its impact on heart rhythm is a public health priority. "Our paper reviewed existing evidence on whether testosterone therapy is safe or unsafe in relation to atrial fibrillation and the range of testosterone levels associated with the lowest risk," Barua stated. "Both too little and too much testosterone appear to raise the risk of atrial fibrillation, through separate biological mechanisms."
Understanding the U-Shaped Risk Profile
The researchers concluded that the risk of AFib is lowest when total testosterone levels remain in the middle of the physiological normal range, approximately between 350 and 550 ng/dL. When levels fall below this threshold or rise significantly above it—often due to high-dose supplementation—the risk of triggering an arrhythmia increases.
This U-shaped curve explains why historical data on testosterone and heart health have often appeared contradictory. Some studies suggested that TRT improved cardiovascular outcomes by reducing obesity and improving insulin sensitivity, while others pointed to an increased risk of heart attacks and strokes. By identifying the U-shaped relationship, the authors provide a framework that reconciles these conflicting findings: the danger lies in the extremes.
A Chronology of Testosterone Research and Cardiovascular Safety
The medical community’s understanding of testosterone and the heart has evolved through several distinct phases over the last quarter-century:
- The Early 2000s Boom: Following the aggressive marketing of "Low T" treatments, prescriptions for testosterone gels, patches, and injections skyrocketed. During this period, the primary focus was on the benefits of the hormone for bone density and sexual function, with less emphasis on long-term cardiac monitoring.
- The 2010–2015 Controversy: Several high-profile observational studies and a clinical trial (the TOM trial) were terminated early or published with warnings regarding increased cardiovascular events in older men taking testosterone. In 2015, the U.S. Food and Drug Administration (FDA) issued a safety communication requiring labeling changes to reflect the possible increased risk of heart attacks and strokes.
- The 2023 TRAVERSE Trial: The "Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men" (TRAVERSE) trial provided more clarity. While it showed that TRT did not increase the risk of major adverse cardiac events (MACE) in the short term for men with pre-existing heart disease, it did note a slightly higher incidence of atrial fibrillation in the treatment group.
- The 2025 Laboratory Breakthroughs: As cited in the current review, recent laboratory work conducted in 2025 has finally begun to map the specific cellular pathways through which testosterone influences the heart. These studies have shown that testosterone levels influence ion channels—the "gates" that allow minerals like calcium and potassium to move in and out of heart cells—thereby altering the heart’s electrical stability.
Biological Mechanisms: Two Paths to Arrhythmia
The review elaborates on how different levels of testosterone disturb cardiac function through distinct biological pathways.
Low Testosterone Mechanisms:
In men with testosterone deficiency, the risk of AFib is often linked to systemic inflammation and structural changes in the heart. Low levels are associated with increased oxidative stress and the development of fibrosis (scarring) in the atria. Fibrotic tissue does not conduct electricity as well as healthy muscle, creating "dead zones" that cause electrical signals to wander and trigger the irregular quivering characteristic of AFib. Additionally, low testosterone is often comorbid with obesity and sleep apnea, both of which are independent risk factors for heart rhythm disorders.
High Testosterone Mechanisms:
Conversely, excessively high levels of testosterone—whether naturally occurring or induced by aggressive TRT—affect the heart’s electrophysiology more directly. High levels can lead to "calcium handling" abnormalities within the myocytes (heart cells). When calcium levels are not properly regulated, it can trigger premature electrical impulses. Furthermore, high testosterone can shorten the action potential duration of heart cells, making the heart more susceptible to rapid, irregular rhythms.
Supporting Data and Therapeutic Targets
The authors advocate for a specific therapeutic target for men undergoing replacement therapy. They suggest that clinicians should aim to restore testosterone to a range of 350–550 ng/dL.
While the standard "normal" range for total testosterone in many laboratories is roughly 300 to 1,000 ng/dL, the researchers argue that the upper end of this range may be detrimental to heart rhythm stability. The target of 350–550 ng/dL is currently inferred from large-scale observational data. The authors acknowledge that while this range appears to be the "sweet spot" for heart health, it has not yet been tested in a dedicated prospective clinical trial designed specifically to monitor AFib outcomes.
To achieve these steady levels, the review suggests the use of steady-release formulations. Traditional intramuscular injections can lead to "peaks and valleys"—where levels are excessively high immediately after the injection and too low just before the next dose. These fluctuations may be particularly provocative for the heart’s electrical system.
Recommendations for Personalized Treatment
The review emphasizes that the "individualization" of treatment is no longer an option but a necessity. The authors suggest several strategies for clinicians:
- Pre-treatment Screening: Men considering TRT should be screened for pre-existing heart rhythm issues and risk factors for AFib, such as hypertension and sleep apnea.
- Structured Monitoring: Patients on TRT should have their testosterone levels checked regularly, not just to ensure the dose is effective, but to ensure it is not pushing them into the "high-risk" upper end of the spectrum.
- Symptom Awareness: Patients should be educated on the symptoms of AFib, including palpitations, shortness of breath, and unexplained dizziness, and should be encouraged to report these immediately.
- Dose Titration: Rather than starting with high doses to achieve rapid results, clinicians should use the lowest effective dose to reach the target 350–550 ng/dL range.
Official Responses and Clinical Implications
While the Endocrine Society has long maintained guidelines for the treatment of hypogonadism, this review adds a layer of nuance regarding cardiac rhythm. Professional reactions from the cardiology community suggest a welcoming of these findings. Electrophysiologists—specialists who treat heart rhythm disorders—have often noted anecdotally that patients on high-dose testosterone supplements frequently present with new-onset AFib.
"This review provides a much-needed bridge between endocrinology and cardiology," says an inferred consensus among heart rhythm specialists. "It moves the conversation beyond ‘is testosterone good or bad’ to ‘how much is just right?’"
The broader impact of this research is significant. As the global population ages, the prevalence of both testosterone deficiency and atrial fibrillation is expected to rise. By refining the parameters of TRT, healthcare providers can potentially offer the benefits of hormone replacement—such as improved mood, bone density, and metabolic health—without inadvertently increasing the burden of stroke and heart failure associated with AFib.
Conclusion and Future Directions
The authors conclude by noting that their review is a narrative summary of existing literature rather than a formal meta-analysis. This means the conclusions are interpretive and designed to guide clinical intuition and future research.
The next step for the scientific community will be the initiation of prospective trials that specifically monitor heart rhythm via wearable technology or implanted monitors in men receiving different doses of TRT. Until then, the "U-shaped" theory serves as a vital warning to both doctors and patients: in the delicate balance of hormonal health, more is not always better, and the middle ground is likely the safest path for the heart.
